Menu
Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
20 On Hatch
Hatch Street Lower, Dublin DUBLIN
Phone: 1135314381700
www.medtronic.com
We recently compiled a list of the 10 Best Medical AI Companies. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against the other medical AI companies. The Need for AI in Healthcare Generally, when you hear the term “artificial intelligence,” your mind jumps straight to semiconductor and big […]
Medtronic has solid competitive advantages and a promising dividend streak. Read what makes MDT stock a long-term buy for conservative investors.
We recently compiled a list of the Jim Cramer Wants You to Watch Out For These 10 Stocks. In this article, we are going to take a look at where Medtronic plc (NYSE:MDT) stands against the other stocks Jim Cramer wants you to watch out for. Jim Cramer noted that Tuesday’s pullback was expected as the […]
Medtronic (MDT) stock shows steady growth, up 9.48% in the past week.
Over the years, Medtronic plc (NYSE: MDT) has constantly strengthened its position in the medical device industry by innovating the product portfolio and expanding into new markets. With demand returning […] The post Medtronic bets on innovation and new technology to drive long-term growth first appeared on AlphaStreet .
Treeview uses augmented- and virtual-reality tools with AI to develop software and metaverse projects. Its clients include Microsoft and Medtronic.
https://www.investing.com/news/company-news/medtronic-shares-target-raised-rating-held-on-steady-growth-93CH-3581487
Medtronic Plc (NYSE: MDT ) reported better-than-expected results for its first quarter on Tuesday. The company posted first-quarter 2025 sales of $7.92 billion, beating the consensus of $7.89 billion. The medical device maker reported adjusted EPS of $1.23, beating the consensus of $1.20. Revenue increased 2.8% year over year, as reported, and 5.3% organic. "Overall revenue outperformance flowed through to the bottom line, with adjusted EPS ahead of expectations," said Gary Corona, Medtronic''s interim chief financial officer. "We''re raising our guidance today as we expect to sustain growth from new product introductions, continue to make … Full story available on Benzinga.com
